EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

TNF Pathway‐Mediated Tolerogenic T‐Cell Trajectory Driven by Allergen Immunotherapy

Helen S Charles, Amr A Gabr, Shu-Hung Wang, Ulrich M Zissler, Sonja Heine, Alexander Heldner, Sebastian Kotz, Lisa Pechtold, Lynn S Zur Bonsen, Dimitrii Pogorelov, Josephine Kau, Mirjam Plaschke und 9 weitere

Allergy · 2026-06 · 81 (6) · 2184-2197

DOI: 10.1111/all.70367 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Allergy, online erschienen am 30.04.2026. Verfasst von Helen S Charles und 20 weiteren Autor:innen. Beteiligte Einrichtung: Center of Allergy and Environment (ZAUM), School of Medicine and Health, Technical University of Munich and Helmholtz Munich, Munich, Germany. Hauptthemen laut MEDLINE: Desensitization, Immunologic, Immune Tolerance, Signal Transduction, Tumor Necrosis Factor-alpha. Die Arbeit nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Allergen immunotherapy (AIT) is a therapeutic approach to restore allergen tolerance and prevent asthma progression. Previous studies have shown exhaustion of T cells and the induction of T cells expressing IL‐17 and FOXP3 early in AIT, which are relevant for the clinical outcome. This study aims to investigate the dynamic transition from type‐3 immunity to a regulatory state observed in the first year during allergic inflammation, as well as the subsequent dysfunction of effector cells during AIT.

Methods

Human and experimental models of allergic airway inflammation were used to assess the impact of AIT on Treg, Tr17 and Th17 cell populations using flow cytometry and proliferation assays. Additionally, human blood samples were analysed using single‐cell transcriptomics to characterise transcriptional signatures associated with the transition from pro‐inflammatory to regulatory states.

Results

AIT restored balance of Tr17 and Treg populations and increased their proliferative capacity, whereas Th17 cells remained functionally impaired. Single‐cell transcriptomics identified Tr17 cells as intermediate states between pro‐inflammatory and regulatory T‐cell programs after AIT. In parallel, AIT reprogrammed intracellular communication networks, with TNF/LTA‐associated signalling pathways emerging as prominent mediators of tolerogenic signalling.

Conclusion

These findings highlight that AIT reprograms immune responses by enhancing regulatory dominance, inducing Tr17 plasticity and leveraging TNF/TNFR2‐mediated tolerance. Understanding the cellular dynamics during AIT suggests that therapeutic strategies aimed at targeting Th17 functional impairment could further enhance treatment efficacy for allergic airway diseases. This insight opens new avenues for refining immunotherapeutic approaches to more effectively restore immune balance and improve patient outcomes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Desensitization, ImmunologicImmune ToleranceSignal TransductionTumor Necrosis Factor-alphaT-Lymphocyte SubsetsT-LymphocytesHumansAnimalsT-Lymphocytes, RegulatoryTh17 CellsAllergensMiceHypersensitivity

Stichwörter der Autor:innen

T cellsTh17 cellsallergen immunotherapyexhaustiontrans‐differentiation

Substanzen

Tumor Necrosis Factor-alphaAllergens

Autor:innen und Institutionen

  • Center of Allergy and Environment (ZAUM), School of Medicine and Health, Technical University of Munich and Helmholtz Munich, Munich, Germany.
  • German Center for Lung Research (DZL), Giessen, Germany.
  • Department of Physiology, Faculty of Veterinary Medicine, Cairo University, Giza, Egypt.
  • Department of Otorhinolaryngology, TUM School of Medicine and Health, Klinikum Rechts der Isar, Technical University of Munich, Munich, Germany.
  • Department of Dermatology and Allergy Biederstein, School of Medicine, Technical University of Munich, Munich, Germany.

ORCID-Profile: Carsten B Schmidt-Weber, Constanze A Jakwerth

Zitieren

APA

Charles, H. S., Gabr, A. A., Wang, S. H., Zissler, U. M., Heine, S., Heldner, A., Kotz, S., Pechtold, L., Bonsen, L. S. Z., Pogorelov, D., Kau, J., Plaschke, M., Hills, M., Guerth, F., Oelsner, M., Ohnmacht, C., Alessandrini, F., Blank, S., Chaker, A. M., …, & Jakwerth, C. A. (2026). TNF Pathway‐Mediated Tolerogenic T‐Cell Trajectory Driven by Allergen Immunotherapy. Allergy, 81(6), 2184-2197. https://doi.org/10.1111/all.70367

Vancouver

Charles HS, Gabr AA, Wang SH, Zissler UM, Heine S, Heldner A, et al. TNF Pathway‐Mediated Tolerogenic T‐Cell Trajectory Driven by Allergen Immunotherapy. Allergy. 2026;81(6):2184-2197. doi:10.1111/all.70367

BibTeX
@article{Charles2026,
  author = {Charles, Helen S and Gabr, Amr A and Wang, Shu-Hung and Zissler, Ulrich M and Heine, Sonja and Heldner, Alexander and Kotz, Sebastian and Pechtold, Lisa and Bonsen, Lynn S Zur and Pogorelov, Dimitrii and Kau, Josephine and Plaschke, Mirjam and Hills, Miriam and Guerth, Ferdinand and Oelsner, Madlen and Ohnmacht, Caspar and Alessandrini, Francesca and Blank, Simon and Chaker, Adam M and Schmidt-Weber, Carsten B and Jakwerth, Constanze A},
  title = {TNF Pathway‐Mediated Tolerogenic T‐Cell Trajectory Driven by Allergen Immunotherapy},
  journal = {Allergy},
  year = {2026},
  volume = {81},
  number = {6},
  pages = {2184--2197},
  doi = {10.1111/all.70367}
}
Kostenlos starten →